SGLT2 Inhibitors Linked to Lower Epilepsy Risk - Takeaway - MDSpire
From the Journals

SGLT2 Inhibitors Linked to Lower Epilepsy Risk

Real-world cohort data show lower epilepsy risk vs DPP-4 inhibitors in older patients with type 2 diabetes

Share

  • 1

    SGLT2 inhibitors linked to lower epilepsy risk in diabetes patients.

  • 2

    Significant reductions: 45% for late-onset epilepsy, 62% for status epilepticus.

  • 3

    Study involved over 1.4 million patients; 60,203 analyzed post-matching.

  • 4

    Benefits observed across demographics, especially in older patients with hypertension.

  • 5

    Limitations include reliance on coded diagnoses and absence of detailed neurological data.

Original Source(s)

SGLT2 Inhibitors Linked to Lower Epilepsy Risk

  • by Kathryn Wighton

  • April 7, 2026

Related Content

Hospital-Treated Infections Linked to Dementia Risk

Investigators identify 29 conditions associated with dementia risk in nationwide registry analysis.

Alzheimer’s Drug Lecanemab Works by “Switching On” the Brain’s Cleanup Cells

Study reveals Fc fragment of antibody is essential for activating microglia to clear amyloid plaques

  • April 7, 2026

  • 3 min
The Hidden Diversity of Amyloid Plaques

A multimodal MSI approach reveals how plaque-associated lipid signatures differ across brain regions in Alzheimer’s disease